Friday, 16 Feb 2018

You are here

Romosuzumab Outperforms Teriparatide in Post-Bisphosphonate Osteoporosis

The STRUCTURE trial results have been reported in Lancet and have shown that after 12 months of therapy, romosozumab (ROMO) had superior gains in bone mineral density (BMD) compared to teriparatide (TER) in women with postmenopausal osteoporosis who have previously taken bisphosphonate therapy.

This phase 3 trial enrolled women (aged ≥55 to ≤90 years) with postmenopausal osteoporosis who had previously received oral bisphosphonate therapy for > 3 years and had a BMD T score of −2·5 or lower at the total hip, femoral neck, or lumbar spine; and a history of fracture. Patients were treated withe either ROMO (210 mg once monthly) or subcutaneous TER (20 μg once daily) and the primary endpoint was the percentage change in BMD at 12 months.

A total of 436 patients were randomized. At 12 months, the mean change in hip BMD was 2·6% (95% CI 2·2 to 3·0) for ROMO and −0·6% (−1·0 to −0·2) for TER treated patients (p<0·0001).

The frequency of adverse events and serious AEs were balanced between treatment groups. The most frequently reported adverse events were nasopharyngitis, hypercalcaemia and arthralgia. There were six (3%) patients in the romosozumab group compared with 12 (6%) in the teriparatide group with adverse events leading to drug withdrawal.

Thus for those requiring a bone-forming agent after bisphosphonates, it appears that the use of the anti-sclerostin drug, romosozumabm, may lead to better gains in hip BMD compared to teriparatide.

To date, more than 11,000 patients have received ROMO in clinical trials. Yet last month the FDA issued a complete response letter to the  manufacturers over concerns about cardiovascular events in subsequent trials. FDA has asked UCB and Amgen to provide additional data on the safety and efficacy of ROMO in their phase 3 active-comparator ARCH study and BRIDGE study.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Teriparatide Superior to Risedronate in the VERO Trial

Lancet reports that in a study teriparatide with risedronate, post-menopausal women with severe osteoporosis had significantly fewer new vertebral and clinical fractures on teriparatide comared to those receiving risedronate.

This trial is one of the first to compare osteoporosis drugs with incident fractures as the primary outcome.

Two Types of Osteoarthritis Based on Cartilage Studies

A report from Annals of Rheumatic Diseases suggests that osteoarthritis (OA) may be two distinct diseases based on genetic studies of articular cartilage. (Citation source: https://buff.ly/2mNtUsL).

RNA sequencing of knee cartilage from 44 OA patients undergoing total knee replacement was compared to 6 additional patients with OA and 10 control patients with non-OA.

New Rise in Hip Fractures Amongst Women

Reuters reports that the incidence of hip fractures in older women in the U.S. is rising after more than a decade of decline, according to a large new study of Medicare recipients.

Calcium and Vitamin D Supplements Do Not Reduce Hip Fractures

Recent JAMA study shows metanalysis of 33 clinical trials and 51,145 participants, showed that calcium, vitamin D, or both affords no decreased risk of hip fractures compared with placebo or no treatment and therefore questions their routine widespread use in the elderly.. 

Community Screening for Fracture Risk in Older Women is Effective and Feasible

A UK Study published in Lancet shows that community-based screening programme for fracture risk in older women is feasible, and may reduce hip fractures. 

Older women, age 70-85 yrs, were identified and participated in the trial and were assessed using the Fracture Risk Assessment Tool (FRAX) with usual management. 12 483 were enrolled and 6233 women randomly assigned to the screening group.